J P Morgan Chase & Co began coverage on shares of Repligen (NASDAQ:RGEN) in a research note released on Tuesday morning. The brokerage issued an overweight rating and a $42.00 price objective on the biotechnology company’s stock.

Several other brokerages have also recently issued reports on RGEN. BidaskClub raised Repligen from a hold rating to a buy rating in a report on Wednesday, August 9th. Zacks Investment Research raised Repligen from a hold rating to a buy rating and set a $46.00 price objective for the company in a report on Saturday, August 12th. TheStreet raised Repligen from a c+ rating to a b- rating in a report on Friday, August 11th. Stephens reaffirmed an overweight rating and set a $50.00 price objective on shares of Repligen in a report on Tuesday, September 26th. Finally, First Analysis raised Repligen from an equal weight rating to an overweight rating and set a $47.00 price objective for the company in a report on Monday, October 2nd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $44.29.

Repligen (RGEN) traded up $0.76 on Tuesday, hitting $35.10. The stock had a trading volume of 413,400 shares, compared to its average volume of 324,877. The firm has a market cap of $1,496.03, a PE ratio of 59.21, a P/E/G ratio of 2.24 and a beta of 1.04. Repligen has a 1-year low of $28.48 and a 1-year high of $46.81.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.11 by $0.04. The business had revenue of $36.58 million during the quarter, compared to analysts’ expectations of $35.69 million. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The company’s quarterly revenue was up 48.2% compared to the same quarter last year. During the same period last year, the firm earned $0.08 EPS. research analysts predict that Repligen will post 0.61 earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of RGEN. BlackRock Inc. increased its position in Repligen by 3.7% during the second quarter. BlackRock Inc. now owns 4,834,853 shares of the biotechnology company’s stock worth $200,355,000 after buying an additional 170,551 shares in the last quarter. TimesSquare Capital Management LLC increased its position in Repligen by 19.8% during the second quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock worth $97,851,000 after buying an additional 390,545 shares in the last quarter. Vanguard Group Inc. increased its position in Repligen by 9.7% during the second quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock worth $82,233,000 after buying an additional 175,191 shares in the last quarter. Conestoga Capital Advisors LLC increased its position in Repligen by 12.5% during the third quarter. Conestoga Capital Advisors LLC now owns 1,453,232 shares of the biotechnology company’s stock worth $55,688,000 after buying an additional 161,427 shares in the last quarter. Finally, FMR LLC increased its position in Repligen by 6.2% during the second quarter. FMR LLC now owns 1,334,090 shares of the biotechnology company’s stock worth $55,285,000 after buying an additional 78,060 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Repligen (RGEN) Coverage Initiated by Analysts at J P Morgan Chase & Co” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/12/06/repligen-rgen-coverage-initiated-by-analysts-at-j-p-morgan-chase-co.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Stock Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related stocks with our FREE daily email newsletter.